Kubat Mehmet, Yazicioglu Mustafa Omer, Bozkirli Bahadir Osman, Gundogdu Riza Haldun
Department of General Surgery, Alanya Training and Research Hospital, Antalya, Turkey.
Department of General Surgery, Ankara City Hospital, Ankara, Turkey.
Sisli Etfal Hastan Tip Bul. 2022 Mar 28;56(1):137-144. doi: 10.14744/SEMB.2021.47587. eCollection 2022.
Nomograms and scoring systems in gastric cancers have been mainly developed based on adequate lymph node (lN) dissections. This study aimed to perform external validation of a nomogram developed for predicting overall survival (OS) in gastric cancer patients with insufficient number of examined LNs (eLNs) and to evaluate its usability as compared with the 8 American Joint Committee on Cancer (AJCC)'s Tumor-Node-Metastasis staging system.
Medical records of 262 patients undergoing complete surgical resection for gastric cancers and having pathologically confirmed diagnosis were retrospectively reviewed. The study included 104 (39.7%) patients (82 males, median age, 60.3 years) with insufficient number of eLNs (<16). The 5-year OS rate was calculated using the nomogram and according to the AJCC system.
The median follow-up period was 37.4 months (range: 0.9-122.9). Of the patients, 69 (66.3%) died and 35 (33.7%) achieved 5-year survival within the follow-up period. The nomogram and the AJCC system predicted OS were significantly lower in patients who died than in those who achieved 5-year survival (p<0.001 for both). According to the receiver operative characteristics-curve, the area under the curve for the nomogram (0.801; 95% CI, 0.715-0.887; p<0.001) was larger than that for the AJCC system (0.754; 95% CI, 0.659-0.849; p<0.001).
The nomogram developed for gastric cancer patients with insufficient number of eLNs (<16) was effective in predicting 5-year OS in our cohort and was superior to the AJCC system.
胃癌的列线图和评分系统主要是基于充分的淋巴结(LN)清扫而开发的。本研究旨在对为检查的淋巴结数量(eLNs)不足的胃癌患者预测总生存期(OS)而开发的列线图进行外部验证,并与美国癌症联合委员会(AJCC)的8版肿瘤-淋巴结-转移分期系统比较评估其可用性。
回顾性分析262例接受胃癌根治性手术切除且病理确诊的患者的病历。该研究纳入了104例(39.7%)eLNs数量不足(<16个)的患者(82例男性,中位年龄60.3岁)。使用列线图并根据AJCC系统计算5年OS率。
中位随访期为37.4个月(范围:0.9 - 122.9个月)。在随访期内,69例(66.3%)患者死亡,35例(33.7%)患者存活5年。死亡患者的列线图和AJCC系统预测的OS显著低于存活5年的患者(两者p<0.001)。根据受试者工作特征曲线,列线图的曲线下面积(0.801;95%CI,0.715 - 0.887;p<0.001)大于AJCC系统(0.754;95%CI,0.659 - 0.849;p<0.001)。
为eLNs数量不足(<16个)的胃癌患者开发的列线图在预测我们队列中的5年OS方面有效,且优于AJCC系统。